Lenz G, Staudt LM: Aggressive lymphomas. N Engl J Med. 2010, 362: 1417-1429. 10.1056/NEJMra0807082.
Article
PubMed
CAS
Google Scholar
Willis TG, Dyer MJ: The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000, 96: 808-822.
PubMed
CAS
Google Scholar
Seifert M, Scholtysik R, Küppers R: Origin and pathogenesis of B cell lymphomas. Methods Mol Biol. 2013, 971: 1-25. 10.1007/978-1-62703-269-8_1.
Article
PubMed
CAS
Google Scholar
Leoncini L, Raphaël M, Stein H, Harris NL, Jaffe ES, Kluin PM: Burkitt lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. Edited by: IARC Press. 2008, Volume 2: 262-264. 4
Google Scholar
Dalla Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM: Human C-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cell. Proc Natl Acad Sci USA. 1982, 79: 7824-7827. 10.1073/pnas.79.24.7824.
Article
PubMed
CAS
PubMed Central
Google Scholar
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 1982, 79: 7837-7841. 10.1073/pnas.79.24.7837.
Article
PubMed
CAS
PubMed Central
Google Scholar
Ambrosio MR, Piccaluga PP, Ponzoni M, Rocca BJ, Malagnino V, Onorati M, De Falco G, Calbi V, Ogwang M, Naresh KN, Pileri SA, Doglioni C, Leoncini L, Lazzi S: The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. PLoS One. 2012, 7: e44315-10.1371/journal.pone.0044315.
Article
PubMed
CAS
PubMed Central
Google Scholar
Newton R, Ziegler J, Beral V, Mbidde E, Carpenter L, Wabinga H, Mbulaiteye S, Appleby P, Reeves G, Jaffe H: Uganda Kaposi’s Sarcoma study group: a case–control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer. 2001, 92: 622-627. 10.1002/1097-0215(20010601)92:5<622::AID-IJC1256>3.0.CO;2-K.
Article
PubMed
CAS
Google Scholar
Perkins AS, Friedberg JW: Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. 2008, 341-348. doi:10.1182/asheducation-2008.1.341
Google Scholar
Magrath I, Jaffe ES, Bhatia K: Burkitt’s lymphoma. Neoplastic hematopathology. Edited by: Knowles DM. 2001, Philadelphia: Lippincott Williams & Wilkins, 953-986.
Google Scholar
Armitage JO, Armitage JO, the Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma study group classification of non-Hodgkin’s lymphoma: the non-Hodgkin’s Lymphoma classification project. Blood. 1997, 89: 3909-3918.
Google Scholar
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004, 104: 634-641. 10.1182/blood-2003-06-2095.
Article
PubMed
CAS
Google Scholar
Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S: Burkitt’s lymphoma. Lancet. 2012, 379: 1234-1244. 10.1016/S0140-6736(11)61177-X.
Article
PubMed
Google Scholar
Magrath IT, Haddy TB, Adde MA: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Onc. 1996, 14: 925-934.
CAS
Google Scholar
Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006, 106: 1569-1580. 10.1002/cncr.21776.
Article
PubMed
CAS
Google Scholar
Depinho RA, Hatton K, Ferrier P, Zimmerman K, Legouy E, Tesfaye A, Collum R, Yancopoulos G, Nisen P, Alt F: Myc family genes: a dispersed multi-gene family. Ann Clin Res. 1986, 18: 284-289.
PubMed
CAS
Google Scholar
Blackwood EM, Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991, 251: 1211-1217. 10.1126/science.2006410.
Article
PubMed
CAS
Google Scholar
Spotts GD, Patel SV, Xiao Q, Hann SR: Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol. 1997, 17: 1459-1468.
Article
PubMed
CAS
PubMed Central
Google Scholar
Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR: Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev. 1998, 12: 3803-3808. 10.1101/gad.12.24.3803.
Article
PubMed
CAS
PubMed Central
Google Scholar
Henriksson M, Lüscher B: Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996, 68: 109-182.
Article
PubMed
CAS
Google Scholar
Vita M, Henriksson M: The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006, 16: 318-330. 10.1016/j.semcancer.2006.07.015.
Article
PubMed
CAS
Google Scholar
Dang CV: MYC on the path to cancer. Cell. 2012, 149: 22-35. 10.1016/j.cell.2012.03.003.
Article
PubMed
CAS
PubMed Central
Google Scholar
Klein U, Tu Y, Stolovitzky GA, Keller JL, Haddad J, Miljkovic V, Cattoretti G, Califano A, Dalla-Favera R: Transcriptional analysis of the B cell germinal center reaction. Proc Nti Acad ScI U S A. 2003, 100: 2639-2644. 10.1073/pnas.0437996100.
Article
CAS
Google Scholar
Gardner LB, Lee LA, Dang CV: C-myc protooncogene. Encyclopedia of cancer. Edited by: Bertino JR. 2002, Amsterdam: Elsevier Science, 555-561.
Chapter
Google Scholar
Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM: Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic agents?. Adv Anat Pathol. 2008, 15: 319-331. 10.1097/PAP.0b013e31818a5c19.
Article
PubMed
CAS
PubMed Central
Google Scholar
Quinn DI, Henshall SM, Sutherland RL: Molecular markers of prostate cancer outcome. Eur J Cancer. 2005, 41: 858-888. 10.1016/j.ejca.2004.12.035.
Article
PubMed
CAS
Google Scholar
Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, Jenkins RB, Pharoah P, Schumacher F, Conti DV, Duggan DJ, Jenkins M, Hopper J, Gallinger S, Newcomb P, Casey G, Sellers TA, Fridley BL: Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet. 2011, 5 (12): 156-
Article
Google Scholar
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG: c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000, 95: 2104-2110.
PubMed
CAS
Google Scholar
Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR: Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA. 2000, 97: 3260-3265. 10.1073/pnas.97.7.3260.
Article
PubMed
CAS
PubMed Central
Google Scholar
Brady G, MacArthur GJ, Farrell PJ: Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 2007, 60: 1397-1402.
PubMed
CAS
PubMed Central
Google Scholar
Philip Kluin et Ed Schuuring: Molecular cytogeneitis of Lymphoma: where do we stand in 2010?. Histopathology. 2011, 58: 128-144. 10.1111/j.1365-2559.2010.03700.x.
Article
PubMed
Google Scholar
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, His ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, et al.: The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012, 44: 1321-1325. 10.1038/ng.2468.
Article
PubMed
CAS
PubMed Central
Google Scholar
Guikema JE, Schuuring E, Kluin PM: Structure and consequences of IGH switch breakpoints in Burkitt lymphoma. J Natl Cancer Inst Monogr. 2008, 39: 32-36.
Article
PubMed
CAS
Google Scholar
Janz S: Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. J Natl Cancer Inst Monogr. 2008, 39: 37-40.
Article
PubMed
CAS
Google Scholar
Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T: The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis. Blood. 2009, 114: 2448-2458. 10.1182/blood-2008-09-181008.
Article
PubMed
CAS
Google Scholar
Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K: Synergy betweenPI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012, 22: 167-179. 10.1016/j.ccr.2012.06.012.
Article
PubMed
CAS
PubMed Central
Google Scholar
Cinti C, Leoncini L, Nyongo A, Ferrari F, Lazzi S, Bellan C, Vatti R, Zamparelli A, Cevenini G, Tosi GM, Claudio PP, Maraldi NM, Tosi P, Giordano A: Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt’s lymphoma subtypes. Am J Pathol. 2000, 156: 751-760. 10.1016/S0002-9440(10)64941-3.
Article
PubMed
CAS
PubMed Central
Google Scholar
Cinti C, Claudio PP, Howard CM, Neri LM, Fu Y, Leoncini L, Tosi GM, Maraldi NM, Giordano A: Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res. 2000, 60: 383-389.
PubMed
CAS
Google Scholar
Leoncini L, Bellan C, Cossu A, Claudio PP, Lazzi S, Cinti C, Cevenini G, Megha T, Laurini L, Luzi P, Orcioni GF, Piccioli M, Pileri S, Giardino C, Tosi P, Giordano A: Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res. 1999, 5: 4065-4072.
PubMed
CAS
Google Scholar
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL: Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999, 13: 2658-2669. 10.1101/gad.13.20.2658.
Article
PubMed
CAS
PubMed Central
Google Scholar
Schmitt CA, McCurrach ME, De Stanchina E, Wallace-Brodeur RR, Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999, 13: 2670-2677. 10.1101/gad.13.20.2670.
Article
PubMed
CAS
PubMed Central
Google Scholar
Roberti A, Rizzolio F, Lucchetti C, De Leval L, Giordano : Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle. 2011, 10: 127-134. 10.4161/cc.10.1.14446.
Article
PubMed
CAS
Google Scholar
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006, 103: 2257-2261. 10.1073/pnas.0510565103.
Article
PubMed
CAS
PubMed Central
Google Scholar
Lawrie CH: MicroRNA expression in lymphoma. Expert Opin Biol Ther. 2007, 7: 1363-1374. 10.1517/14712598.7.9.1363.
Article
PubMed
CAS
Google Scholar
De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L: Role of EBV in microRNA dysregulation in Burkitt lymphoma. Semin Cancer Biol. 2009, 19: 401-406. 10.1016/j.semcancer.2009.07.003.
Article
PubMed
CAS
Google Scholar
Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, Dastugue N, Penther D, Barin C, Collonge-Rame MA, Baranger L, Terré C, Nadal N, Lippert E, Laï JL, Cabrol C, Tigaud I, Herens C, Hagemeijer A, Raphael M, Libouton JM, Poirel HA: Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement. Genes Chromosomes Cancer. 2013, 52: 81-92. 10.1002/gcc.22008.
Article
PubMed
CAS
Google Scholar
García JL, Hernandez JM, Gutiérrez NC, Flores T, González D, Calasanz MJ, Martínez-Climent JA, Piris MA, Lopéz-Capitán C, González MB, Odero MD, San Miguel JF: Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt’s lymphoma: a cytogenetic and comparative genomic hybridization study. Leukemia. 2003, 17: 2016-2024. 10.1038/sj.leu.2403080.
Article
PubMed
Google Scholar
Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W: Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol. 2010, 23: 909-920. 10.1038/modpathol.2010.76.
Article
PubMed
CAS
Google Scholar
Boerma EG, Siebert R, Kluin PM, Baudis M: Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia. 2009, 23: 225-234. 10.1038/leu.2008.281.
Article
PubMed
CAS
Google Scholar
Poirel HA, Cairo MS, Heerema NA, Swansbury J, Aupérin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphaël M, McCarthy K, Sposto R, Gerrard M, Bernheim A, Patte C, FAB/LMB 96 International study committee: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009, 23: 323-331. 10.1038/leu.2008.312.
Article
PubMed
CAS
PubMed Central
Google Scholar
Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, Da Costa L, Pérot C, Ribrag V, Patte C, Wiels J, Bernheim A: High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS One. 2009, 4: e7089-10.1371/journal.pone.0007089.
Article
PubMed
PubMed Central
Google Scholar
Wring G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM: A gene expression- based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003, 100: 9991-9996. 10.1073/pnas.1732008100.
Article
Google Scholar
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, et al.: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006, 354: 2419-2430. 10.1056/NEJMoa055351.
Article
PubMed
CAS
Google Scholar
Bellan C, Stefano L, De Giulia F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol. 2010, 28: 53-56.
PubMed
Google Scholar
Naresh KN, Ibrahim HA, Lazzi S, Rince P, Onorati M, Ambrosio MR, Bilhou-Nabera C, Amen F, Reid A, Mawanda M, Calbi V, Ogwang M, Rogena E, Byakika B, Sayed S, Moshi E, Mwakigonja A, Raphael M, Magrath I, Leoncini L: Diagnosis of Burkitt lymphoma using an algorithmic approach-applicable in both resource-poor and resource-rich countries. Br J Haematol. 2011, 154: 770-776. 10.1111/j.1365-2141.2011.08771.x.
Article
PubMed
Google Scholar
Salaverria I, Siebert R: The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011, 29: 1835-1843. 10.1200/JCO.2010.32.8385.
Article
PubMed
Google Scholar
Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ: B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012, 25: 145-156. 10.1038/modpathol.2011.147.
Article
PubMed
CAS
Google Scholar
Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ: Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012, 118: 1566-1573. 10.1002/cncr.26433.
Article
PubMed
CAS
Google Scholar
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008, 105: 13520-13525. 10.1073/pnas.0804295105.
Article
PubMed
CAS
PubMed Central
Google Scholar
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005, 106: 3183-3190. 10.1182/blood-2005-04-1399.
Article
PubMed
CAS
PubMed Central
Google Scholar
Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, Siebert R: FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006, 8: 141-151. 10.2353/jmoldx.2006.050083.
Article
PubMed
CAS
PubMed Central
Google Scholar
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB: Immunohistochemical double-hit score is a strong predictor of outcome in patientswith diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012, 30: 3460-3467. 10.1200/JCO.2011.41.4342.
Article
PubMed
CAS
Google Scholar
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group: MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013, 121: 2253-2263. 10.1182/blood-2012-06-435842.
Article
PubMed
CAS
Google Scholar
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012, 30: 3452-3459. 10.1200/JCO.2011.41.0985.
Article
PubMed
CAS
PubMed Central
Google Scholar
Guikema JE, De Boer C, Haralambieva E, Smit LA, Van Noesel CJ, Schuuring E, Kluin PM: IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination. Genes Chromosomes Cancer. 2006, 45: 808-819. 10.1002/gcc.20345.
Article
PubMed
CAS
Google Scholar